Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN versus XACIATO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN versus XACIATO.
CLEOCIN vs XACIATO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing peptide bond formation.
150-450 mg orally every 6 hours; 300-600 mg IM or IV every 6-8 hours; maximum 4.8 g/day IV.
Administer one vaginal gel (50 mg clindamycin) intravaginally as a single dose.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 8-12 hours in severe hepatic impairment; dialyzable but not clinically used for Clostridium difficile infection.
Terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. Half-life may be prolonged in patients with severe hepatic impairment or neonates.
Approximately 10% renal as active drug and metabolites, 90% fecal/biliary via enterohepatic circulation; <1% unchanged in urine.
Clindamycin is primarily excreted via bile (approximately 85% of the dose as metabolites and parent drug) and feces (10%), with renal excretion accounting for less than 10%.
Category C
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic